Lutetium-177 DOTATATE Therapy in the Management of Neuroendocrine Tumors

#287

Introduction: Peptide receptor radionuclide therapy (PRRT) is a specific targeted treatment for NETs expressing somatostatin receptors. 177Lu-DOTATATE is one of several newly available compounds for this treatment.

Aim(s): We review a case of NET seen in our institutions. The patient received 177Lu-DOTATE in a presentation aimed at trainees.

Materials and methods: A 32-year-old male underwent resection of a retroperitoneal paraganglioma in 1999 following presentation with abdominal pain. He presented in 2007 with paroxysmal hypertension, and elevated urinary catecholamines. MRI, 123I-MIBG and 68Ga-DOTATATE PET-CT scans showed metastatic disease with multiple bone metastases.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Carroll R, Tan T, Todd J, Al-Nahhas A, Bomanji J,

Keywords: 177Lutetium-DOTATATE therapy, neuroendocrine tumor, paraganglioma, SDHB,